Evidence map›Paper›PMID 42347598›Full record

ArticleVaccines2026

Evolution of National Influenza Vaccine Platform: From Comprehensive Preclinical Safety Validation of Trivalent Influenza Vaccine to Streamlined Immunogenicity of Quadrivalent Formulation.

Luka Dragačević, Veljko Blagojević, Marko Vasić, Rajna Minić, Ivana Ćuruvija, Ivana Prijić, Raisa Petrović, Darko Rogić, Irena Živković

Abstract read
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luka DragačevićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0003-1662-0493
Veljko BlagojevićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0002-8491-9924
Marko VasićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0003-2115-5901
Rajna MinićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0003-2941-9246
Ivana ĆuruvijaInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0001-7009-3933
Ivana PrijićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0001-8201-2459
Raisa PetrovićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.
Darko RogićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.
Irena ŽivkovićInstitute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11000 Belgrade, Serbia.ORCID 0000-0002-4074-590X

Funding

Institute of Virology, Vaccines and Sera "Torlak" 451-03-136/2025-03/200177Ministry of Science, Technological Development, and Innovation 451-03-136/2025-03/200177
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

influenza vaccinepandemic preparednesspreclinical evaluationtechnology transfervaccine manufacturing platform

Identifiers

PMID42347598
PMCPMC13307876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.